Zheng Quan Shi Bao Wang·2025-10-31 09:59Core Insights - The assisted reproductive concept sector saw a rise of 3.23%, ranking 8th among concept sectors, with 69 stocks increasing in value, including notable gains from companies like Caina Co., Ltd. (20% limit up), Zhongsheng Pharmaceutical (limit up), and Kangzhi Pharmaceutical, which rose by 17.47%, 10.99%, and 9.98% respectively [1][6] - The sector experienced a net inflow of 811 million yuan from main funds, with 38 stocks receiving net inflows, and 23 stocks seeing inflows exceeding 10 million yuan. Zhongsheng Pharmaceutical led with a net inflow of 305 million yuan, followed by Guangsheng Pharmaceutical and Anke Bio, with net inflows of 272 million yuan and 88 million yuan respectively [1][2] Sector Performance - The assisted reproductive concept sector was among the top gainers, with a daily increase of 3.23%, while other sectors like recombinant proteins and cell immunotherapy also performed well, increasing by 3.72% and 3.58% respectively [1] - Conversely, sectors such as cultivated diamonds and national big fund holdings faced declines, both dropping by 2.96% [1] Fund Flow Analysis - The leading stocks in terms of fund inflow ratios included Zhongsheng Pharmaceutical (20.95%), Tianyao Pharmaceutical (10.99%), and Caina Co., Ltd. (10.65%) [2][3] - The top stocks by main fund flow included Zhongsheng Pharmaceutical with 304.73 million yuan, Guangsheng Pharmaceutical with 272.34 million yuan, and Anke Bio with 88.06 million yuan [2][3] Notable Stock Movements - Significant stock movements included Zhongsheng Pharmaceutical and Caina Co., Ltd. achieving limit up status, while companies like Changchun High-tech and *ST Suwu experienced declines of 2.55% and 1.98% respectively [1][5] - Other notable gainers included Kangzhi Pharmaceutical and Nanjing Momo Biological, which rose by 17.47% and 9.98% respectively [1][4]